Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
2.
Biol Reprod ; 98(3): 309-322, 2018 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-29324974

RESUMO

Gestational choriocarcinomas are derived from placental trophoblast cells, with HLA-C being the only class I polymorphic molecule expressed. However, choriocarcinomas have not been profiled for endoplasmic reticulum aminopeptidase 2 (ERAP2) expression. ERAP2 trims peptides presented by human leukocyte antigens (HLA) that have shown to modulate immune response. Over 50% of choriocarcinomas we screened lack ERAP2 expression, which suggests that the absence of ERAP2 expression allows immune evasion of choriocarcinoma cells. We demonstrate that the ability of choriocarcinoma cells to activate lymphocytes was lowest with cells lacking ERAP2 (JEG-3) or HLA-C (JAr). This observation suggests that activation is dependent on expression of both ERAP2 and HLA-C molecules. In addition, an ERAP2 variant in which lysine is changed to asparagine (K392N) results in increased trimming activity (165-fold) for hydrophobic peptides and biologically never been detected. We hypothesize that homozygosity for the N392 ERAP2 variant is prohibited because it modulates the immune recognition of placental trophoblasts. We demonstrate that NK-cell activation and killing were significantly dependent on forced expression of the N392 ERAP2 isoform in JEG-3 cells. Cytotoxicity was confirmed by 7AAD killing assays showing that N392 ERAP2-isoform expressing JEG-3 cells had the highest percentage of apoptotic cells independent of the expression level of CD11a on lymphocytes. This is the first report showing that N392 ERAP2 promotes an immune clearance pathway for choriocarcinoma cells, and provides an explanation for why embryonic homozygosity for the N392 ERAP2 variant is not detected in any population.


Assuntos
Aminopeptidases/metabolismo , Coriocarcinoma/imunologia , Neoplasias do Colo do Útero/imunologia , Linhagem Celular Tumoral , Coriocarcinoma/metabolismo , Feminino , Humanos , Interferon gama/farmacologia , Gravidez , Trofoblastos/efeitos dos fármacos , Trofoblastos/imunologia , Trofoblastos/metabolismo , Neoplasias do Colo do Útero/metabolismo
3.
Ocul Immunol Inflamm ; 25(6): 811-819, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27380422

RESUMO

PURPOSE: B cells participate in diverse retinal immunopathologies. Endothelial adhesion molecules and chemokines direct leukocyte trafficking. We examined the involvement of three molecular signals in retinal transendothelial migration of human B cells: ICAM-1, VCAM-1, and CXCL13. METHODS: Peripheral blood B cells were isolated by negative selection. Migration was studied in transwells populated with human retinal endothelial monolayers, using antibody to block ICAM-1 or VCAM-1. Retinal expression of CXCL13 was investigated. RESULTS: B cells crossed retinal endothelium. ICAM-1 blockade significantly reduced migration when results for all subjects were combined, and for a majority when results were analyzed by individual. This effect was irrespective of the presence or absence of CXCL13, although CXCL13 increased migration. CXCL13 was detected in neural retina and retinal pigment epithelium. Endothelial cells of some retinal vessels presented CXCL13 protein. CONCLUSION: ICAM-1 blockade may be an effective treatment in some patients with retinal diseases that involve B cells.


Assuntos
Linfócitos B/fisiologia , Movimento Celular/fisiologia , Quimiocina CXCL13/fisiologia , Molécula 1 de Adesão Intercelular/fisiologia , Retina/fisiologia , Molécula 1 de Adesão de Célula Vascular/fisiologia , Endotélio Vascular/metabolismo , Humanos , Imuno-Histoquímica , Imunofenotipagem , Epitélio Pigmentado da Retina/fisiologia , Vasos Retinianos , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Transdução de Sinais , Migração Transendotelial e Transepitelial/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA